Another note could there be a connection between smithkline beecham and roche where SKB forgoes revenue from relenza in return for roche giving up on one of its drugs to the benefit of SKB back when SKB decided to pull back from relenza???
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
